pluripotent

Organoids are a handful of cells of a given type derived from pluripotent stem cells and growing together.

A woman in China received a transplant of pancreatic beta cells derived from her own, induced pluripotent stem cells.

One advantage of iPS (induced pluripotent stem cells) is the lack of rejection - these are derived from your own fibroblasts.

If pluripotent cells turn out to cause problems, then we could always engineer a kill switch to make sure they die off after the limb is regrown.

They already have a way of making induced pluripotent stem cells without using embryos.

It is likely far easier and safer to work with pluripotent cells from an adult who is also both the donor and recipient.

The example that comes to mind is pluripotent stem cells (see e.g.

It turns out that you can induce pluripotency with all four Yamanaka factors, but there's a significant risk of the pluripotent cells turning into cancer.

In the past researchers have shown that reprogramming adult cells to create induced pluripotent stem cells sweeps away some specific forms of damage observed in old cells.

Introducing pluripotent cells seems like a recipe for disaster.

Depending on when they differentiate, there would no doubt be a bunch of growing pluripotent cells, including enough backup cells to start over if batches are somehow contaminated.

So the best way to get induced pluripotent stem cells is through the Yamanaka factors, which are proteins coded for by genes which are not expressed in mature cells.

The article notes, "This process of regeneration is made possible by olfactory ensheathing cells (OECs), which provide a pathway for the fibres to grow back." In other words, this was not an experimental treatment with stem cells (pluripotent cells).

And so this is how most tissues in an organism work: constant turnover and production of new mature cells from tissue-specific stem cell precursors (as opposed to "pluripotent" stem cells which can in theory produce any cell type, not just a certain tissue).

True, Sana above are attempting to extend their gene engineering ("HIP") to stem cells as well > apply the HIP technology to develop therapeutic candidates at scale, including both pluripotent stem cells and donor-derived allogeneic CAR T cells.

Kind of like the "zygote" forking model (early in the main process lifetime, a zygote process gets forked off, and when the main process wants another worker it asks the zygote to fork one off) except that the "zygote" is more like an induced pluripotent stem cell, having been reverted from an adult state.

Pluripotent cells work fine in many animals with no apparent problems and avoid all of the issues with the clone approach.